Purpose: To compare the effects of two anti-angiogenic drugs, bevacizumab and a cytosolic phospholipase A2-a inhibitor (AVX235), on the relationship between vascular structure and dynamic contrast enhanced (DCE)-MRI measurements in a patient-derived breast cancer xenograft model. Methods: Mice bearing MAS98.12 tumors were randomized into three groups: bevacizumab-treated (n ¼ 9), AVX235-treated (n ¼ 9), and control (n ¼ 8). DCE-MRI was performed pre-and post-treatment. Median initial area under the concentration-time curve (IAUC 60 ) and volume transfer constant (K trans ) were computed for each tumor. Tumors were excised for ex vivo micro-CT (computed tomography) angiography, from which the vascular surface area (VSA) and fractional blood volume (FBV) were computed. Spearman correlation coefficients (q) were computed to evaluate the associations between the DCE-MRI and micro-CT parameters. Results: With the groups pooled, IAUC 60 and K trans correlated significantly with VSA (q ¼ 0.475 and 0.527; P ¼ 0.019 and 0.008). There were no significant correlations within the control group. There were various significant correlations within the treatment groups, but the correlations in the bevacizumab group were of opposite sign, for example, K trans versus FBV: AVX235,
INTRODUCTION
Dynamic contrast enhanced (DCE)-MRI provides information on vascular function (blood flow, permeability), and DCE-MRI biomarkers are frequently incorporated into clinical trials of anti-angiogenic therapies (1) . Currently recommended biomarkers to measure include the initial area under the contrast agent concentration-time curve at 60 seconds postinjection (IAUC 60 ) and the volume transfer constant (K trans ) derived from the Tofts model (2) (3) (4) . Both of these are composite parameters that depend on a combination of blood flow and vessel permeability/surface area product (PS). The dependence of these DCE-MRI parameters on multiple factors can make their physiological interpretations ambiguous. However, they have shown promise as biomarkers of cancer treatment response, suggesting that physiologically specific biomarkers may not be essential for clinical decision making (5) .
Still, separate measurements of biological factors can be interesting and helpful, for example, in studying drug mechanisms of action or in certain clinical cases (6, 7) . Generalized pharmacokinetic models can provide individual estimates of blood plasma volume fraction (v p ), extravascular-extracellular space volume fraction (v e ), blood flow, and PS (8) , but these models have not been widely adopted for DCE-MRI analysis.
Regardless of the method of analysis, DCE-MRI is often discussed in the context of blood flow and permeability (ie, vascular function) whereas the surface area component of the PS product (ie, vascular structure) is largely ignored. A search for "DCE-MRI" on PubMed (15 August 2016) yielded 1,929 results; of those, 246 also include the term "flow", 342 include "permeability", and only 40 include "surface area". This illustrates that relatively few studies have explicitly investigated how vascular morphology influences DCE-MRI measurements or how this relationship is affected by treatment (9) (10) (11) . (Throughout the paper, vascular morphology/structure refer to the "macroscopic" form of the vascular network and not cellular morphology of the endothelium and perivascular components.)
In this study, we addressed these questions by comparing in vivo DCE-MRI parameters to ex vivo micro-CT (computed tomography) vascular morphometrics and histology in a patient-derived xenograft model of breast cancer treated with two different anti-angiogenic agents: 1) bevacizumab (Avastin; Genentech Inc., South San Francisco, CA, USA), a monoclonal antibody against vascular endothelial growth factor A, the main driver of tumor angiogenesis (12) , and 2) AVX235 (Avexxin AS, Trondheim, Norway), a small-molecule inhibitor of group IVA cytosolic phospholipase A 2 -a, a proinflammatory and proangiogenic enzyme that has emerged as a potential therapeutic target in various cancers (13) (14) (15) (16) .
METHODS

Experimental Design
MAS98.12
patient-derived basal-like/triple-negative breast cancer xenografts were bilaterally and orthotopically transplanted into the thoracic mammary fat pads of 26 female Hsd:Athymic Nude-Foxn1 nu mice. Establishment and maintenance of the tumor model is described in Bergamaschi et al (17) . Details of animal housing and handling can be found in Kim et al (16) . All procedures and experiments involving animals were approved by the Norwegian Animal Research Authority and carried out according to the European Convention for the Protection of Vertebrates used for Scientific Purposes.
Mice were randomly assigned to one of three groups when the long axis of the larger tumor reached $8 mm as measured by calipers. Baseline MRI was performed on all mice (day 0). Afterward, one group (n ¼ 9) received bevacizumab (5 mg/kg intraperitoneally, 0.5 mg/mL saline) on days 0 and 3; another group (n ¼ 9) received daily doses of AVX235 (45 mg/kg intraperitoneally, 22.5 mg/mL dimethyl sulfoxide [DMSO] ) from day 0 to day 6; and a control group (n ¼ 8) received daily doses of 100% DMSO (2 mL/kg intraperitoneally) from day 0 to day 6. All mice were scanned again on day 4, after which the bevacizumab-treated mice were sacrificed; AVX235-treated and control mice were scanned again on day 7 before being sacrificed. For the control and AVX235 groups, the DCE-MRI data collected on day 4 was not included in this study.
Previous studies have demonstrated that both drugs inhibit long-term growth of this tumor model (16, 18) . The short duration of this study was chosen in order to investigate the early vascular effects of the drugs.
MRI
MRI was performed on a 7 Tesla scanner (BioSpec 70/20 Avance III; Bruker Biospin, Ettlingen, Germany) using an 86-mm excitation volume coil and a mouse brain quadrature receiver surface coil. Mice were anesthetized with isoflurane (2.0-2.5% in 67% air/33% O 2 , 0.6 L/min); isoflurane levels were adjusted as needed to maintain a respiration rate of $60 breaths/min. Animals' body temperatures were monitored with a rectal probe and controlled using a small-animal monitoring system (Model 1030;, SAII, Stony Brook, NY, USA Tumor ROIs, which excluded skin and subcutaneous fat around tumors, were manually drawn on the 3D images for tumor volume measurements and on the highresolution 2D images and down-sampled to the resolution of the other images for DCE-MRI analysis. The enhancing fraction (EF; fraction of tumor voxels with signal enhancement >50% 1 minute after contrast agent administration) (19, 20) and maps of IAUC 60 and the extended Tofts model parameters-K trans , v e , and v pwere computed from the DCE-MRI data. A previously measured population-based biexponential arterial input function (AIF) was used for pharmacokinetic analysis (21) . Tumor-wise parameter medians were computed from the maps. Nonenhancing voxels and voxels with poor fits (R 2 < 0.5) were excluded from these computations and all subsequent analyses.
Micro-CT
Immediately after the final MRI session, mice were sacrificed by perfusion fixation and perfused with Microfil (Flow Tech, Inc., Carver, MA, USA), a radiopaque vascular casting agent. Then, tumors were excised and scanned on a SkyScan 1176 micro-CT system (Bruker microCT, Kontich, Belgium) at 9-mm isotropic resolution. Tumor blood vessels were segmented from micro-CT images using a Hessian-based filtering method (22, 23) . Tumor masks, which excluded any skin and subcutaneous fat remaining after excision, were manually drawn on the raw micro-CT images. From the segmented vessels and tumor masks, fractional blood volume (FBV), vessel surface area (VSA) normalized to tumor volume, and median and 90th percentile distances to the nearest vessel (DNV and DNV90) were computed for each tumor. DNV is inversely related to overall vessel density, whereas DNV90 is sensitive to the presence of large avascular regions. These large avascular regions in the micro-CT images that corresponded to nonenhancing areas in the DCE-MRI image and necrotic areas in the histology sections were extracted from the tumor masks by thresholding the DNV maps. Thresholds were manually determined upon visual comparison of the three imaging modalities. These regions were excluded from the tumor volume measurements used to compute FBV and VSA. Details of the perfusion and micro-CT image acquisition, reconstruction, and processing can be found in Kim et al (16) .
Histology
After micro-CT imaging, tumors were cut in half approximately along the MRI slice plane and embedded in paraffin. Four-mm-thick sections were cut from the center of each tumor and stained with hematoxylin erythrosine saffron (HES) for identifying viable tumor tissue or doublestained with lectin (Griffonia simplicifolia lectin I; Vector Laboratories, Burlingame, CA, USA) as an endothelial marker for quantifying vascularization and anti-Ki67 antibody (monoclonal rabbit anti-human Ki67 with crossreactivity to mouse; Abcam, Cambridge, UK) as a proliferation marker. Nonoverlapping 10 Â fields were acquired from each lectin-stained tumor section using an Olympus BX41 microscope (Olympus Norge AS, Oslo, Norway). Six to 10 fields were acquired for each section to obtain good coverage of the viable tumor regions. Red-green-blue (RGB) images were converted to hue-saturation-value (HSV) images, and lectin-stained endothelium was segmented by simple thresholding of the hue, saturation, and value channels. The same manually defined thresholds for each channel were used for all images. From the binarized images, the vascular area fraction was computed for each tumor.
Statistical Analysis
All statistical analyses were performed in MATLAB (R2015a; The MathWorks, Inc., Natick, MA, USA). Kruskal-Wallis one-way analysis of variance (ANOVA) was performed to test for a significant difference in normalized tumor volume between the three experimental groups on day 4. A two-tailed Wilcoxon rank-sum test was performed to test for a significant difference in normalized tumor volume between control and AVX235-treated tumors on day 7. One-way multivariate ANOVA (MAN-OVA), Kruskal-Wallis one-way ANOVA, and post-hoc Tukey's honest significant difference (HSD) tests were used for intergroup comparisons of micro-CT parameters and changes in DCE-MRI parameters. In addition to testing for differences in the multivariate means of multiple groups, the manova1 MATLAB function computes canonical variables-orthogonal linear combinations of the original predictor variables that maximize the separation between groups. Scatter plots of the first and second canonical variables were generated to visualize the separation between groups. Spearman correlation coefficients (q) were computed to measure the correlation between the "functional" DCE-MRI parameters (EF, IAUC 60 , and K trans ), micro-CT parameters, and histological vascular area fraction. For all tests, a ¼ 0.05.
RESULTS
Pretreatment DCE-MRI data were not acquired for 1 bevacizumab-treated mouse because of unsuccessful tail vein cannulation. From the micro-CT data set, one control and one bevacizumab-treated tumor were excluded because of incomplete Microfil perfusion. 3 for the bevacizumab-treated group. Kruskal-Wallis one-way ANOVA and subsequent post-hoc Tukey's HSD tests showed that median day 0 tumor volume was significantly larger in the bevacizumab group than in the AVX235 group (P ¼ 0.042). Therefore, tumor volumes were normalized to day 0 values to evaluate the therapeutic effects on tumor growth (Fig. 1 ). There were no significant differences in median normalized tumor volumes between the three groups on day 4 (P ¼ 0.135, one-way ANOVA) or between the control and AVX235 groups on day 7 (P ¼ 0.200, two-tailed Wilcoxon rank-sum test).
Neither Therapy Resulted in Early Tumor Growth Inhibition
DCE-MRI Did Not Detect Differential Treatment Responses
One-way MANOVA determined that there were no significant differences between the three groups based on the pre-to post-treatment changes in the DCE-MRI parameters (P ¼ 0.330). This is visualized by the scatter plot of the first and second canonical variables (c1 vs c2), which shows a high degree of overlap between the groups (Fig. 2a) . There is some partial separation between the control and bevacizumab-treated groups, with the AVX235-treated group in between. When looking at the DCE-MRI parameters individually (Fig. 2b-f) , it becomes apparent that bevacizumab had therapeutic effects; for example, there was a clear decrease in IAUC 60 (Fig. 2c) . However, when accounting for multiple groups and parameters, these effects were not statistically significant. 
Micro-CT Revealed Treatment-Related Differences in Vascular Morphology
Micro-CT revealed significant differences in vascular morphology between the experimental groups (P < 0.001, one-way MANOVA). There is a clear separation between the bevacizumab-treated group and the other two groups along c1 and good separation between the AVX235-treated and control groups along c2 (Fig. 3a) .
VSA and FBV were largest in the control group and smallest in the bevacizumab group (Fig. 3b,c) , and the opposite trend was observed for DNV (Fig. 3d ). These parameters were significantly different in the bevacizumab group compared to controls (P < 0.05, post-hoc Tukey's HSD test). There was a significant difference in VSA between the AVX235 and bevacizumab groups (P < 0.05). The difference in FBV between the two treatment groups was close to statistical significance (P ¼ 0.054). AVX235-treated tumors had the largest DNV90 (Fig. 3e) , which was significantly different from the DNV90 in control tumors (P < 0.01).
DCE-MRI Functional Parameters Correlate With Micro-CT Vascular Morphometrics
Pooled (all tumors from all groups) and group-wise Spearman q values between DCE-MRI and micro-CT parameters are presented in Table 1 .
With the groups pooled, there was a moderate, but significant, positive correlation between IAUC 60 and VSA (P ¼ 0.019); K trans also positively correlated with VSA (P ¼ 0.008). There was a negative correlation between EF and DNV90 (P ¼ 0.048).
Correlation coefficients for individual groups revealed interesting effects of treatment on the relationship between DCE-MRI and micro-CT measurements. First, there were no significant correlations in the control group. Second, the correlations in the bevacizumab group were of the opposite sign as those in the AVX235 group.
Figures 4 and 5 present these trends. With all three groups pooled, IAUC 60 and K trans generally increased with VSA and FBV (Fig. 4) . This was also the case for the AVX235 group on its own. DCE-MRI and micro-CT parameter values were lower in the bevacizumab group than in the other groups, contributing to the pooled positive correlations. However, there was a negative correlation between the DCE-MRI and micro-CT parameters within the bevacizumab group.
Despite this unexpected inverse relationship in the bevacizumab group, we qualitatively observed a direct spatial relationship between DCE-MRI and micro-CT within individual tumors. Figure 5c illustrates thisthe top tumor is less vascularized than the bottom based on the micro-CT data (center column), but has greater IAUC 60 in the viable tumor area (left); but within each tumor, relatively highly vascularized areas correspond to high perfusion (central region of the top tumor) and vice versa (lower right region of the bottom tumor). 
Tumor Perfusion Inversely Correlates With Histological Vascularization
Overall, there was a moderate, but significant (P ¼ 0.018), negative correlation between IAUC 60 and histological vascular area fraction (Table 2 ; Fig. 6a ). The intragroup correlation between IAUC 60 and vascular area fraction was significant for the control group; the intragroup correlation between K trans and vascular area fraction was significant for the control and bevacizumab groups ( Table 2 ; Fig. 6a,b ).
There were no significant correlations between histological vascular area fraction and micro-CT parameters (Table 2 ; Fig. 6c,d ). The correlation with FBV in the bevacizumab group was good, but fell just short of statistical significance (P ¼ 0.058). Of note, correlations between micro-CT and histologically measured vascularization were positive in the bevacizumab group whereas all other correlations were negative or very weak.
DISCUSSION
Although tumor growth inhibition did not reach statistical significance within the time frame of this experiment, previous studies have demonstrated that both AVX235 and bevacizumab inhibit vascular proliferation and longterm tumor growth in the MAS98.12 model used here (16, 18) . The DCE-MRI data from this study indicate that the two drugs did not have significantly different effects, but the micro-CT data did reveal significant differences between the experimental groups. The differences between groups are further emphasized by the correlations between the DCE-MRI and micro-CT parameters. Before comparing the group-wise correlations, it is worth discussing the pooled correlations and the general dependence of DCE-MRI functional parameters on vascular structure.
Pooled Correlations Show That Vascular Structure Influences DCE-MRI Parameters
The significant positive correlations between IAUC 60 and K trans and VSA demonstrate that DCE-MRI parameters are not only influenced by vascular function, but can also be highly dependent on vascular surface area (4). The commonly used extended Tofts model is most appropriate and accurate under high flow conditions, in which contrast agent extravasation is PS limited (24) . Pharmacokinetic analysis can be restricted to fastenhancing voxels to ensure that the data satisfy this condition, as was done here. In addition, most tumor blood vessels are characteristically leaky and thus highly permeable to the low molecular weight gadolinium-based contrast agents used in the clinic. Thus, vascular surface area can be the determining factor in contrast agent kinetics in some cases.
It may seem contradictory that IAUC 60 correlated positively with VSA, but negatively with histological vascular area fraction. However, the three imaging modalities report different things about the vasculature. This makes it difficult to use one technique to validate another, but combining these complementary image data can provide deeper, more-nuanced insights into tumor vascular biology. To make sound interpretations, one must be mindful of exactly what these methods measure and how they differ. DCE-MRI characterizes tumor perfusion by functional vessels, micro-CT visualizes the structure of these functional vessels, and histological staining marks endothelial cells regardless of vessel functionality.
The lack of correlation between micro-CT and histology can be explained by the dysfunctional nature of tumor vasculature, combined with the different vessel populations that are detected by each imaging modality. The negative correlation between DCE-MRI and histology suggests that increased vascularization from dysregulated tumor angiogenesis does not always translate to increased perfusion and may actually be counterproductive. Figures 5b (top row) and 5c (bottom row) show examples of tumor regions that were not perfused based on DCE-MRI and micro-CT, but were still viable and vascularized based on histology.
Similarly, a previous study found a negative correlation between K trans and histological microvessel density in colorectal cancer xenografts (25) . But other studies have reported moderate-to-strong positive correlations between DCE-MRI and histological parameters (9, 10, 26) , whereas others showed weak or no correlations (27) (28) (29) . These discrepancies could be attributed to the wide range of data acquisition and analysis methods that were used or to the different patient populations, preclinical cancer models, or treatment regimens investigated. Considering the high degree of heterogeneity between different types of cancer and even within the same cancer type, there is likely concomitant heterogeneity in the relationship between tumor vascularization and perfusion. 
Group-wise Correlations Illustrate the Complexity and Mutability of the Interpretation of DCE-MRI Parameters
The group-wise correlations revealed interesting and unexpected differences between the three experimental groups. The lack of significant correlations between DCE-MRI and micro-CT parameters in the control group suggests large intertumor heterogeneity in vascular phenotype or a decoupling of structure and function in the tumor vasculature. This may be a consequence of the characteristically chaotic and hyperpermeable vessels that are produced by pathological tumor angiogenesis. In contrast, the direct relationships between DCE-MRI and micro-CT in AVX235-treated tumors suggest that cytosolic phospholipase A2 inhibition resulted in vascular normalization and subsequent recoupling of vascular structure and function.
Analogously, a recent study showed that K trans did not correlate with an independent measure of PS product (made by quantifying the leakage of a radioactive tracer) in the control group of a rat model of lung cancer brain metastasis. But there was a positive correlation after bevacizumab treatment, which the researchers attributed to therapy-induced vascular normalization (30) .
The inverse associations in the bevacizumab-treated group in our study are harder to interpret, but may indicate improved blood flow as a result of treatmentinduced vascular pruning and remodeling. This hypothesis is supported by the increase in EF and borderline significant positive correlation between FBV and histological vascular area fraction in the bevacizumab group; that is, after bevacizumab treatment, the amount of functional vasculature is more closely associated with the total amount of vasculature, as is expected in healthy tissue. The negative correlations between DCE-MRI and micro-CT, then, reflect the negative correlation between DCE-MRI and histology.
This suggests that in the bevacizumab group, contrastagent delivery to the tumor was not directly determined by vascular surface area, but instead by blood flow. Given that dysregulated angiogenesis and subsequent hypervascularization can lead to vascular insufficiency in tumors, it is reasonable that fewer, well-functioning vessels can deliver greater blood flow (31, 32) . One possible mechanistic explanation for this is that decreased vascular permeability resulted in decreased tumor interstitial fluid pressure (a previously reported effect of bevacizumab treatment) and thus improved tumor perfusion and delivery of contrast agent to tumor tissue (33) (34) (35) .
This could also explain the increase in EF observed after bevacizumab treatment. Whereas EF often decreases after anti-angiogenic and anti-vascular therapies (7, 19, 36) , other studies have reported treatment-induced increases in EF, including a previous study investigating the effects of bevacizumab on the tumor model used here (20, 37, 38) .
The disparate correlations between the treatment groups could be the consequence of two distinct mechanisms of action leading to differential modifications of the tumor vasculature. Alternatively, the difference could represent two distinct time points in a common pharmacological progression. Despite the large amount of research on tumor angiogenesis and anti-angiogenic therapy, the mechanisms of action of these drugs are still not fully understood (39) . The results presented here reflect this complexity of tumor biology and pharmacodynamics.
Study Limitations
Limitations of this study include the use of a single population-based AIF, which could have changed significantly during treatment, and manual injection of contrast agents. The use of a power injector for DCE-MRI would have resulted in more uniform AIFs across animals and time points, and a perfusion pump would have ensured consistent Microfil perfusion at physiological pressures and thus minimized vessel distortion. Another limitation was the nine-micron spatial resolution of the micro-CT scanner, which is not enough to detect the smallest capillary-sized vessels. This may have biased the data if the proportion of these microvessels varied between experimental groups. As mentioned above, postmortem staining of blood vessels in histological sections does not discriminate between perfused and nonperfused vessels. For the purposes of validating DCE-MRI and other in vivo perfusion imaging techniques, methods such as labeling functional vessels by intravital lectin perfusion would be more suitable (40) . Given some of the unexpected correlations found in this study, the generalizability and reproducibility of these vascular structurefunction associations should be tested using different tumor models, therapies, and contrast agents.
CONCLUSION
DCE-MRI parameters such as IAUC 60 and K trans , largely regarded as measures of vessel permeability or blood flow (ie, vascular function), can be greatly influenced by vascular surface area. The relative weights of these three factors can be significantly altered by anti-angiogenic therapy, making the interpretation of DCE-MRI measurements difficult. This highlights one of the challenges of adopting DCE-MRI parameters as clinical biomarkers and emphasizes the need for a better understanding of tumor angiogenesis and of the mechanisms of action of antiangiogenic agents.
